Griebel G, Perrault G, Sanger D J
CNS Research Department, Synthélabo Recherche, Bagneux, France.
Psychopharmacology (Berl). 1998 Jul;138(1):55-66. doi: 10.1007/s002130050645.
The present series of experiments compared the behavioral effects of the novel non-peptide CRF antagonist CP-154,526 with those of diazepam and the 5-HT1A receptor partial agonist buspirone in classical animal models of anxiety including conflict tests (punished lever pressing and punished drinking tests in rats) and exploratory models (elevated plus-maze test in rats, light/dark choice and free-exploration tests in mice), and a recently developed mouse defense test battery (MDTB) which has been validated for the screening of anxiolytic drugs. Results from both conflict procedures showed that diazepam (2.5-10 mg/kg, i.p.) produced clear anxiolytic-like effects, whereas buspirone (2.5 mg/kg, i.p.) displayed anticonflict activity in the punished drinking test only. CP-154,526 (0.6-20 mg/kg) was devoid of significant activity in both procedures. In the elevated plus-maze, diazepam (2 mg/kg, i.p.) produced significant effects on traditional (i.e. spatio-temporal) and ethologically derived (i.e. risk assessment and directed exploration) indices of anxiety. Buspirone (1-4 mg/kg, i.p.) reduced risk assessment activities only, and CP-154,526 (0.6-20 mg/kg, i.p.) did not modify the indices of anxiety in the elevated plus-maze. In the light/dark test, diazepam (2.5-5 mg/kg, i.p.) and CP-154,526 (10-40 mg/kg, i.p.) affected all behavioral indices of anxiety, while buspirone reduced risk assessment activities at the highest doses only (10 and 15 mg/kg, i.p.). In the free-exploration test, diazepam (1 mg/kg, i.p.) reduced avoidance responses towards novelty, as indicated by the increase in exploratory activity in a novel compartment and the decrease in risk assessment. CP-154,526 failed to affect the former behavior and weakly reduced the latter (5 and 20 mg/kg, i.p.). Buspirone (1.25-5 mg/kg, i.p.) was inactive in this test. Finally, in the MDTB, diazepam (0.5-3 mg/kg, i.p.) attenuated all defensive reactions of mice confronted with a rat stimulus (i.e. flight, risk assessment and defensive attack) or with a situation associated with this threat (i.e. contextual defense). Buspirone (1.25-5 mg/kg, i.p.) reduced defensive attack and contextual defense, while CP-154,526 (5-20 mg/kg, i.p.) affected all defensive behaviors, with the exception of one risk assessment measure. The finding that CP-154,526 displayed positive effects in mice but not in rats may be due to increased sensitivity to environmental stress of the strains used (i.e. BALB/c, Swiss) and/or to the fact that animals were exposed to unavoidable stress stimuli which may lead to a significant activation of the CRF system. Although in mice the anxiety-reducing potential of CP-154,526 is superior to that of the atypical anxiolytic buspirone, it is smaller in terms of the magnitude of the effects and the number of indices of anxiety affected than that of diazepam.
本系列实验在焦虑经典动物模型中比较了新型非肽类促肾上腺皮质激素释放因子(CRF)拮抗剂CP - 154,526与地西泮以及5 - HT1A受体部分激动剂丁螺环酮的行为学效应,这些模型包括冲突试验(大鼠的惩罚性杠杆按压和惩罚性饮水试验)和探索性模型(大鼠的高架十字迷宫试验、小鼠的明暗选择和自由探索试验),以及最近开发的已被验证可用于筛选抗焦虑药物的小鼠防御试验组(MDTB)。两种冲突试验的结果表明,地西泮(2.5 - 10毫克/千克,腹腔注射)产生明显的抗焦虑样效应,而丁螺环酮(2.5毫克/千克,腹腔注射)仅在惩罚性饮水试验中表现出抗冲突活性。CP - 154,526(0.6 - 20毫克/千克)在这两种试验中均无显著活性。在高架十字迷宫试验中,地西泮(2毫克/千克,腹腔注射)对传统(即时空)和行为学衍生(即风险评估和定向探索)焦虑指标产生显著影响。丁螺环酮(1 - 4毫克/千克,腹腔注射)仅降低风险评估活动,而CP - 154,526(0.6 - 20毫克/千克,腹腔注射)未改变高架十字迷宫试验中的焦虑指标。在明暗试验中,地西泮(2.5 - 5毫克/千克,腹腔注射)和CP - 154,526(10 - 40毫克/千克,腹腔注射)影响所有焦虑行为指标,而丁螺环酮仅在最高剂量(10和15毫克/千克,腹腔注射)时降低风险评估活动。在自由探索试验中,地西泮(1毫克/千克,腹腔注射)减少对新奇事物的回避反应,表现为在新隔室中的探索活动增加和风险评估减少。CP - 154,526未能影响前一种行为,对后一种行为的降低作用较弱(5和20毫克/千克,腹腔注射)。丁螺环酮(1.25 - 5毫克/千克,腹腔注射)在该试验中无活性。最后,在MDTB试验中,地西泮(0.5 - 3毫克/千克,腹腔注射)减弱了小鼠面对大鼠刺激(即逃跑、风险评估和防御性攻击)或与该威胁相关的情境(即情境防御)时的所有防御反应。丁螺环酮(1.25 - 5毫克/千克,腹腔注射)减少防御性攻击和情境防御,而CP - 154,526(5 - 20毫克/千克,腹腔注射)影响所有防御行为,但有一种风险评估指标除外。CP - 154,526在小鼠中显示出积极作用而在大鼠中未显示,这一发现可能是由于所用品系(即BALB/c、瑞士)对环境应激的敏感性增加和/或动物暴露于不可避免的应激刺激下,这可能导致CRF系统的显著激活。尽管在小鼠中CP - 154,526的抗焦虑潜力优于非典型抗焦虑药丁螺环酮,但在效应大小和受影响的焦虑指标数量方面,其作用小于地西泮。